Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF) (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Depreciation & Amortization (CF) data on record, last reported at $21000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 133.33% year-over-year to $21000.0; the TTM value through Dec 2025 reached $59000.0, down 13.24%, while the annual FY2025 figure was $59000.0, 13.24% down from the prior year.
  • Depreciation & Amortization (CF) reached $21000.0 in Q4 2025 per TGTX's latest filing, up from $17000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $80000.0 in Q4 2021 and bottomed at $8000.0 in Q1 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $46150.0, with a median of $48500.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 84.93% in 2024, then soared 133.33% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $80000.0 in 2021, then fell by 8.75% to $73000.0 in 2022, then crashed by 47.95% to $38000.0 in 2023, then plummeted by 76.32% to $9000.0 in 2024, then skyrocketed by 133.33% to $21000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $21000.0 in Q4 2025, $17000.0 in Q3 2025, and $13000.0 in Q2 2025.